The purpose of this site is to provide meaningful information regarding the use of herbal preparations to promote general health. This site does not claim or attempt to provide any medical advice and should not be considered to be a medical resource. The products and preparations listed on this site are not certified or approved by the FDA for the treatment of any malady. The people whose testimony and opinions are reported on this site are not in any way associated with this site. Their statements are included for informational purposes only and must be evaluated by the reader on their own merits. The statements reported, positive or otherwise, do not constitute an endorsement by the people who made them.
After the Kefauver Harris Amendment was passed in 1962, the . FDA began the DESI review process to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards, including Dianabol.  In 1965, the FDA pressured CIBA to further document its legitimate medical uses, and re-approved the drug for treating post-menopausal osteoporosis and pituitary-deficient dwarfism .  After CIBA's patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the .